Featured in this issue

POLICIES
Doriol de Solà-Morales et al.: Innovation in new medicines: systematic review
Andrés Pichon-Riviere et al.: HTA in Latin America: good practice principles
Andres Pichon-Riviere et al.: Stakeholder involvement in HTA in Latin America
Wija Oortwijn et al.: Role of horizon scanning revisited
Yot Teeravattananon et al.: HTAsiaLink development and its key to success

METHODS
Axel C. Muhlbacher et al.: Patient priorities for treatment attributes in adjunctive drug therapy
Julie Polisena et al.: HTA methods guidelines for MDs
Murray Krahn et al.: The Ontario decision framework
Karla Hernandez-Villafuerte et al.: PFS as a surrogate for OS in oncology
Julie Polisena et al.: Environmental impact assessment of a health technology

ASSESSMENTS
Herbert J.A. Rolden et al.: Review of economic models on dabigatran in AF
Phuong Lien Tran et al.: Digital images performance for cervical cancer screening
Luiza Raquel Grazziotin et al.: HTA of amphotericin B lipid formulations
The Journal welcomes submissions of articles that evaluate health technologies to support health policy or practice decisions, or discuss methods of assessing such technologies; please see Journal Aims and Scope for full details. Manuscripts are reviewed by the Editors and members of the Editorial Board. Those that pass proceed to an international review process, which usually is completed within 4 to 10 weeks. Accepted manuscripts will be published within 4 to 6 months. Articles must be in English. Spelling, punctuation, and punctuation should conform to the 15th Edition of The Chicago Manual of Style (University of Chicago Press).

MANUSCRIPT SUBMISSION AND REVIEW. All manuscript submissions to the International Journal of Technology Assessment in Health Care must be made electronically via ScholarOne Manuscripts, at the website: http://mc.manuscriptcentral.com/thc

Please follow the detailed instructions on the website to avoid delays. The authors are asked to provide contact information and they may supply review comments. The website automatically acknowledges receipt of the manuscript and provides a manuscript reference number. Every effort will be made to provide the author with a rapid review. Correspondence must quote manuscript reference number and should be sent by email to the Editorial Office at ITAR@cambridge.org.

PREPARATION OF MANUSCRIPT. The manuscript, including all references, must be provided in Word or RTF format, double spaced on 8½ x 11 inch or A4 page sizes, with at least 1 inch (2.54 cm) margins. Manuscripts should typically have less than 4000 words, including the abstract of 250 words maximum, and usually no more than 25 references. Manuscripts should be as follows:
1) cover sheet, including short title,
2) abstract and keywords,
3) acknowledgments, including source of funding,
4) text,
5) references,
6) tables with titles, and
7) figures, with captions on a separate page.

The Journal accepts no more than four tables or figures altogether for the published version. Tables and figures exceeding these limits may be posted on the Cambridge journals web site (www.journals.cambridge.org) as supplementary materials. Supplementary tables and figures should be numbered separately from the final tables and figures in the published issue, beginning with Supplementary Table 1 and Supplementary Figure 1. The Journal accepts but does not require onscript footnotes or appendices.

Where relevant, manuscripts should include a paragraph on the policy implications of the findings of the study. Acronyms should be clearly spelled out on first use. The use of product trade names should be avoided, generic names should be used unless where discussion of proprietary brands is essential to the manuscript.

COVER SHEET AND COVER LETTER. A cover letter, signed by all authors, must attest that all authors contributed to the conception and design of the study and interpretation of data and the writing of the paper; a cover sheet has approved the version being submitted; and the content has not been published nor is being considered for publication elsewhere.

As relevant to the content of the paper, the letter should also attest to the fact that any research with human or animal subjects conforms to the legal and ethical standards of the country in which it was performed. All authors must disclose any financial arrangements with companies whose products are discussed in the paper or their competitors; such information will not be revealed to reviewers but may be included in a suitable format in the final publication if the manuscript is accepted.

Access the Conflict of Interest disclosure form at the website: http://mc.manuscriptcentral.com/thc

The cover letter should also provide all authors full names, professional degrees, and institutional mailing addresses.
CONTENTS

Policies

224  Defining innovation with respect to new medicines: A systematic review from a payer perspective
Oriol de Solà-Morales, David Cunningham, Mathias Flume, Paul M. Overton, Natalie Shalet and Stefano Capri

241  Health technology assessment for decision making in Latin America: Good practice principles
Andrés Pichon-Riviere, Natalie C. Soto, Federico Ariel Augustovski, Sebastián García Martí and Laura Sampietro-Colom

248  Stakeholder involvement in the health technology assessment process in Latin America
Andres Pichon-Riviere, Natalie Soto, Federico Augustovski and Laura Sampietro-Colom

254  How can health systems prepare for new and emerging health technologies? The role of horizon scanning revisited
Wija Oortwijn, Laura Sampietro-Colom, Fay Habens and Rebecca Trowman

260  Historical development of the HTAsiaLink Network and its key determinants of success
Yot Teerawattananon, Karlena Luz, Chalarntorn Yothasmutra, Raoh-Fang Pwu, Jeonghoon Ahn, Asrul Akmal Shafie, Kalipso Chalkidou, Sripen Tantivess, Benjarin Santatiwongchai, Waranya Rattanavipapong and Saudamini Dabak

Methods

267  Patient priorities for treatment attributes in adjunctive drug therapy of severe hypercholesterolemia in Germany: An analytic hierarchy process
Axel C. Mühlbacher, Anika Kaczynski, Franz-Werner Dippel and Susanne Bethge

276  Health technology assessment methods guidelines for medical devices: How can we address the gaps? The International Federation of Medical and Biological Engineering perspective
Julie Polisena, Rossana Castaldo, Oriana Ciani, Carlo Federici, Simone Borsci, Matteo Ritrovato, Daniel Clark and Leandro Pecchia

290  Development of the Ontario decision framework: A values based framework for health technology assessment
Murray Krahn, Fiona Miller, Ahmed Bayyouni, Ann-Sylvia Brooker, Frank Wagner, Shawn Winsor, Mita Giacomini, Ron Goeree, Holger Schünemann, Gabrielle van der Velde, Stephen Petersen, Nancy Stikich and Irfan Dhalla

300  Challenges and methodologies in using progression free survival as a surrogate for overall survival in Oncology
Karla Hernandez-Villafuerte, Alastair Fischer and Nicholas Latimer

317  Environmental impact assessment of a health technology: A scoping review
Julie Polisena, Gino De Angelis, David Kaunelis and Ibáñez-Gutierrez-Ibarluzea

Assessments

327  The gap between economic evaluations and clinical practice: A systematic review of economic evaluations on dabigatran for atrial fibrillation
Herbert J.A. Rolden, Gert Jan van der Wilt, Angela H.E.M. Maas and Janneke P.C. Grutters

337  Performance of smartphone-based digital images for cervical cancer screening in a low-resource context
Phuong Lien Tran, Caroline Benski, Manuela Viviano, Patrick Petignat, Christophe Combescure, Jeromine Jinoro, Josea Lea Herinianasolo and Pierre Vassilakos

343  Comparative effectiveness and safety between amphotericin B lipid-formulations: A systematic review
Luiza Raquel Grazziotin, Leila Beltrami Moreira and Maria Angelica Pires Ferreira